Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has received a consensus recommendation of “Hold” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $4.16.

SNSS has been the subject of a number of recent research reports. Zacks Investment Research cut Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. ValuEngine raised Sunesis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald set a $3.00 target price on Sunesis Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, December 5th. Cowen reaffirmed a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Thursday, November 2nd. Finally, Oppenheimer initiated coverage on Sunesis Pharmaceuticals in a report on Tuesday, November 21st. They issued an “outperform” rating and a $7.00 target price for the company.

Shares of Sunesis Pharmaceuticals (SNSS) traded down $0.18 during mid-day trading on Friday, hitting $5.55. The company had a trading volume of 118,063 shares, compared to its average volume of 142,149. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34. Sunesis Pharmaceuticals has a twelve month low of $1.82 and a twelve month high of $6.24. The company has a market cap of $193.66, a P/E ratio of -2.99 and a beta of 1.71.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Balyasny Asset Management LLC acquired a new position in Sunesis Pharmaceuticals in the 2nd quarter worth about $5,400,000. Vanguard Group Inc. increased its holdings in Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after purchasing an additional 23,819 shares in the last quarter. BlackRock Inc. increased its holdings in Sunesis Pharmaceuticals by 9.5% in the 4th quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock worth $482,000 after purchasing an additional 11,351 shares in the last quarter. Wells Fargo & Company MN increased its holdings in Sunesis Pharmaceuticals by 127.6% in the 3rd quarter. Wells Fargo & Company MN now owns 95,247 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 53,396 shares in the last quarter. Finally, Virtu KCG Holdings LLC acquired a new position in Sunesis Pharmaceuticals in the 2nd quarter worth about $208,000. 39.46% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2018/02/09/sunesis-pharmaceuticals-inc-snss-receives-4-16-average-price-target-from-analysts.html.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.